MARKET

ORXOF

ORXOF

Orexo Ab
OTCQX
2.900
NaN%
Closed 09:30 05/20 EDT
OPEN
--
PREV CLOSE
2.900
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
2.900
52 WEEK LOW
2.550
MARKET CAP
--
P/E (TTM)
1.449
1D
5D
1M
3M
1Y
5Y
1D
OREXO AB - SINGLE NASAL DOSE OF OX390 ACHIEVES TARGETED THERAPEUTIC EXPOSURE
Reuters · 1d ago
Orexo posts positive in‑vivo data for nasal overdose reversal candidate OX390
TipRanks · 1d ago
Orexo reports positive in-vivo study data for OX390 nasal atipamezole absorption
PUBT · 1d ago
Orexo AGM Backs Board, Expands Capital Flexibility and Incentive Plans
TipRanks · 05/07 15:36
Orexo AGM re-elects Friedrich von Bohlen und Halbach as board chair
PUBT · 05/07 15:03
Orexo publishes transcript of Q1 2026 earnings call
PUBT · 04/28 12:50
Orexo Deepens R&D Push as Losses Widen and Bond Redeemed Early
TipRanks · 04/28 05:33
Orexo Q1 operating loss narrows to SEK 75 million; net sales fall to SEK 5 million
PUBT · 04/28 05:05
More
About ORXOF
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.

Webull offers Orexo AB stock information, including OTCQX: ORXOF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORXOF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORXOF stock methods without spending real money on the virtual paper trading platform.